Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ENSIGN GROUP, INCENSG · Entity 3521 | Director | July 20, 2026 | July 22, 2026 |
| HERBALIFE LTD.HLF · Entity 4842 | Director · Chairman and CEO | May 10, 2022 | May 11, 2022 |
| MAGELLAN HEALTH INCMGLN · Entity 131790 | Director | May 24, 2018 | May 25, 2018 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ENSIGN GROUP, INC
Report date July 20, 2026 · Filed July 22, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 9,503.149 |
Reported balance
After 2026-07-20 transaction · row 1
1 source rowRow 1 · 2026-07-20 · Sale · Disposed 392 · Balance 9,503.149 F1: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on July 31, 2025. |
Filing footnotes · ownership attribution and instrument terms
F1: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on July 31, 2025.
HERBALIFE LTD.
Report date May 10, 2022 · Filed May 11, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 134,745 |
Reported balance
After 2022-05-10 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2022-05-10 · Purchase · Acquired 4,222 · Balance 134,745 F1: This transaction was executed in multiple trades at prices ranging from $23.38 to $23.72. The price reported reflects the weighted average purchase price of $23.5514. The reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected. F2: Balance reflects shares purchased through the Issuer's Herbalife Ltd. Employee Stock Purchase Plan since last reported on Form 4. |
Filing footnotes · ownership attribution and instrument terms
F1: This transaction was executed in multiple trades at prices ranging from $23.38 to $23.72. The price reported reflects the weighted average purchase price of $23.5514. The reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected.
F2: Balance reflects shares purchased through the Issuer's Herbalife Ltd. Employee Stock Purchase Plan since last reported on Form 4.
MAGELLAN HEALTH INC
Report date May 24, 2018 · Filed May 25, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary Common Stock, $0.01 par valueSEC Table I · non-derivative | Direct | 9,267 |
Reported balance
After 2018-05-24 transaction · row 1
1 source rowRow 1 · 2018-05-24 · Grant · Acquired 1,685 · Balance 9,267 F1: Annual director restricted stock award pursuant to 2016 Management Incentive Plan. Shares shall vest fully on the date of the 2019 Annual Meeting of Shareholders. F2: Not applicable. |
Filing footnotes · ownership attribution and instrument terms
F1: Annual director restricted stock award pursuant to 2016 Management Incentive Plan. Shares shall vest fully on the date of the 2019 Annual Meeting of Shareholders.
F2: Not applicable.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
bluebird bio, Inc.
Report date May 30, 2025 · Filed June 03, 2025
Section 16 reporting ended · disclosed 2025-06-03. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Ending reported balance
After 2025-06-02 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2025-05-30 · Other · Disposed 1,323 · Balance 1,245 F1: In connection with the terms of an Agreement and Plan of Merger, dated as of February 21, 2025 (as amended, the "Merger Agreement"), by and among the Issuer, Beacon Parent Holdings, L.P. ("Parent") and Beacon Merger Sub, Inc., an indirect wholly owned subsidiary of Parent ("Purchaser"), Purchaser completed a tender offer for shares of the Issuer's Common Stock. Tendering stockholders were given the option to receive per share consideration of either (x) $3.00 in cash per share, subject to any applicable withholding taxes and without interest thereon, plus one contingent value right ("CVR") per share, representing the right to receive one contingent payment of $6.84, in cash, subject to any applicable withholding taxes and without interest thereon, upon achievement of the specified milestone or (y) $5.00 in cash per share, subject to any applicable withholding taxes and without interest thereon (collectively, the "Offer Price"). F2: (Continued from footnote 1) After completion of the tender offer, Purchaser merged with and into the Issuer (the "Merger"), effective as of June 2, 2025 (the "Effective Time"), with the Issuer continuing as the surviving entity and a wholly owned subsidiary of Parent. Row 2 · 2025-06-02 · Disposition to issuer · Disposed 1,245 · Balance 0 F3: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each time-based restricted stock unit award with respect to shares that is, at the time of determination, subject to vesting or forfeiture conditions and that is not a PSU Award (as defined below) (but including, for clarity, any PSU Award that is subject solely to service-based vesting conditions as of the Effective Time) ("RSU Award") that is outstanding as of immediately prior thereto, shall (a) accelerate and become fully vested, and (b) by virtue of the Merger automatically (except as otherwise provided in the Merger Agreement) and without any action on the part of the Issuer, Parent or the holder thereof, be canceled and terminated and converted into the right to receive F4: (Continued from footnote 3) (i) an amount in cash equal to the product of the number of shares underlying such RSU Award immediately prior to the Effective Time and $3.00 in cash, subject to any applicable withholding taxes and without interest thereon plus (ii) one CVR with respect to each share subject to such RSU Award immediately prior to the Effective Time. |
Filing footnotes · ownership attribution and instrument terms
F1: In connection with the terms of an Agreement and Plan of Merger, dated as of February 21, 2025 (as amended, the "Merger Agreement"), by and among the Issuer, Beacon Parent Holdings, L.P. ("Parent") and Beacon Merger Sub, Inc., an indirect wholly owned subsidiary of Parent ("Purchaser"), Purchaser completed a tender offer for shares of the Issuer's Common Stock. Tendering stockholders were given the option to receive per share consideration of either (x) $3.00 in cash per share, subject to any applicable withholding taxes and without interest thereon, plus one contingent value right ("CVR") per share, representing the right to receive one contingent payment of $6.84, in cash, subject to any applicable withholding taxes and without interest thereon, upon achievement of the specified milestone or (y) $5.00 in cash per share, subject to any applicable withholding taxes and without interest thereon (collectively, the "Offer Price").
F2: (Continued from footnote 1) After completion of the tender offer, Purchaser merged with and into the Issuer (the "Merger"), effective as of June 2, 2025 (the "Effective Time"), with the Issuer continuing as the surviving entity and a wholly owned subsidiary of Parent.
F3: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each time-based restricted stock unit award with respect to shares that is, at the time of determination, subject to vesting or forfeiture conditions and that is not a PSU Award (as defined below) (but including, for clarity, any PSU Award that is subject solely to service-based vesting conditions as of the Effective Time) ("RSU Award") that is outstanding as of immediately prior thereto, shall (a) accelerate and become fully vested, and (b) by virtue of the Merger automatically (except as otherwise provided in the Merger Agreement) and without any action on the part of the Issuer, Parent or the holder thereof, be canceled and terminated and converted into the right to receive
F4: (Continued from footnote 3) (i) an amount in cash equal to the product of the number of shares underlying such RSU Award immediately prior to the Effective Time and $3.00 in cash, subject to any applicable withholding taxes and without interest thereon plus (ii) one CVR with respect to each share subject to such RSU Award immediately prior to the Effective Time.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 20, 2026 Filed Jul 22, 2026 21:50 UTC | ENSIGN GROUP, INC ENSG · Entity 3521 | SaleCommon Stock | 392 | $171.06 | $67,055.52 |
DisclosureSEC source: 0001627893-26-000012 · wk-form4_1784757011.xml · nonDerivative · entry 1 Agwunobi John O · CIK 0001627893 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 9,503.149 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on July 31, 2025. Read SEC document |
| July 15, 2026 Filed Jul 17, 2026 20:21 UTC | ENSIGN GROUP, INC ENSG · Entity 3521 | GrantCommon Stock | 600 | $0.00 | $0.00 |
DisclosureSEC source: 0001627893-26-000010 · wk-form4_1784319695.xml · nonDerivative · entry 1 Agwunobi John O · CIK 0001627893 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,895.149 F1 · shares: These shares vest in three equal annual installments beginning July 15, 2027. Read SEC document |
| April 20, 2026 Filed Apr 22, 2026 20:59 UTC | ENSIGN GROUP, INC ENSG · Entity 3521 | SaleCommon Stock | 392 | $199.97 | $78,388.24 |
DisclosureSEC source: 0001627893-26-000008 · wk-form4_1776891570.xml · nonDerivative · entry 1 Agwunobi John O · CIK 0001627893 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 9,295.149 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on July 31, 2025. Read SEC document |
| April 15, 2026 Filed Apr 17, 2026 22:47 UTC | ENSIGN GROUP, INC ENSG · Entity 3521 | GrantCommon Stock | 600 | $0.00 | $0.00 |
DisclosureSEC source: 0001627893-26-000006 · wk-form4_1776466026.xml · nonDerivative · entry 1 Agwunobi John O · CIK 0001627893 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,687.149 F1 · shares: These shares vest in three equal annual installments beginning April 15, 2027. Read SEC document |
| January 21, 2026 Filed Jan 22, 2026 22:23 UTC | ENSIGN GROUP, INC ENSG · Entity 3521 | SaleCommon Stock | 146 | $178.31 | $26,033.26 |
DisclosureSEC source: 0001627893-26-000004 · wk-form4_1769120587.xml · nonDerivative · entry 2 Agwunobi John O · CIK 0001627893 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 9,087.149 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on July 31, 2025. Read SEC document |
| January 20, 2026 Filed Jan 22, 2026 22:23 UTC | ENSIGN GROUP, INC ENSG · Entity 3521 | SaleCommon Stock | 246 | $179.82 | $44,235.72 |
DisclosureSEC source: 0001627893-26-000004 · wk-form4_1769120587.xml · nonDerivative · entry 1 Agwunobi John O · CIK 0001627893 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 9,233.149 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on July 31, 2025. Read SEC document |
| January 15, 2026 Filed Jan 20, 2026 21:24 UTC | ENSIGN GROUP, INC ENSG · Entity 3521 | GrantCommon Stock | 600 | $0.00 | $0.00 |
DisclosureSEC source: 0001627893-26-000002 · wk-form4_1768944242.xml · nonDerivative · entry 1 Agwunobi John O · CIK 0001627893 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,479.149 F1 · shares: These shares vest in three equal annual installments beginning January 15, 2027. Read SEC document |
| November 06, 2025 Filed Nov 7, 2025 22:56 UTC | ENSIGN GROUP, INC ENSG · Entity 3521 | SaleCommon Stock | 246 | $188.87 | $46,462.02 |
DisclosureSEC source: 0001627893-25-000007 · wk-form4_1762556177.xml · nonDerivative · entry 1 Agwunobi John O · CIK 0001627893 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 8,879.149 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on July 31, 2025. Read SEC document |
| October 15, 2025 Filed Oct 17, 2025 20:43 UTC | ENSIGN GROUP, INC ENSG · Entity 3521 | GrantCommon Stock | 600 | $0.00 | $0.00 |
DisclosureSEC source: 0001627893-25-000005 · wk-form4_1760733792.xml · nonDerivative · entry 1 Agwunobi John O · CIK 0001627893 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,125.149 F1 · shares: These shares vest in three equal annual installments beginning October 15, 2026. Read SEC document |
| July 15, 2025 Filed Jul 17, 2025 20:20 UTC | ENSIGN GROUP, INC ENSG · Entity 3521 | GrantCommon Stock | 600 | $0.00 | $0.00 |
DisclosureSEC source: 0001125376-25-000133 · wk-form4_1752783602.xml · nonDerivative · entry 1 Agwunobi John O · CIK 0001627893 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,525.149 F1 · shares: These shares vest in three equal annual installments beginning July 15, 2026. Read SEC document |
| June 02, 2025 Filed Jun 3, 2025 21:46 UTC | bluebird bio, Inc. BLUE · Entity 78923 | Disposition to issuerCommon Stock | 1,245 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-25-081163 · ownership.xml · nonDerivative · entry 2 Agwunobi John O · CIK 0001627893 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F3 · price: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each time-based restricted stock unit award with respect to shares that is, at the time of determination, subject to vesting or forfeiture conditions and that is not a PSU Award (as defined below) (but including, for clarity, any PSU Award that is subject solely to service-based vesting conditions as of the Effective Time) ("RSU Award") that is outstanding as of immediately prior thereto, shall (a) accelerate and become fully vested, and (b) by virtue of the Merger automatically (except as otherwise provided in the Merger Agreement) and without any action on the part of the Issuer, Parent or the holder thereof, be canceled and terminated and converted into the right to receive F4 · price: (Continued from footnote 3) (i) an amount in cash equal to the product of the number of shares underlying such RSU Award immediately prior to the Effective Time and $3.00 in cash, subject to any applicable withholding taxes and without interest thereon plus (ii) one CVR with respect to each share subject to such RSU Award immediately prior to the Effective Time. Read SEC document |
| May 30, 2025 Filed Jun 3, 2025 21:46 UTC | bluebird bio, Inc. BLUE · Entity 78923 | OtherCommon Stock | 1,323 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-25-081163 · ownership.xml · nonDerivative · entry 1 Agwunobi John O · CIK 0001627893 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,245 F1 · price: In connection with the terms of an Agreement and Plan of Merger, dated as of February 21, 2025 (as amended, the "Merger Agreement"), by and among the Issuer, Beacon Parent Holdings, L.P. ("Parent") and Beacon Merger Sub, Inc., an indirect wholly owned subsidiary of Parent ("Purchaser"), Purchaser completed a tender offer for shares of the Issuer's Common Stock. Tendering stockholders were given the option to receive per share consideration of either (x) $3.00 in cash per share, subject to any applicable withholding taxes and without interest thereon, plus one contingent value right ("CVR") per share, representing the right to receive one contingent payment of $6.84, in cash, subject to any applicable withholding taxes and without interest thereon, upon achievement of the specified milestone or (y) $5.00 in cash per share, subject to any applicable withholding taxes and without interest thereon (collectively, the "Offer Price"). F2 · price: (Continued from footnote 1) After completion of the tender offer, Purchaser merged with and into the Issuer (the "Merger"), effective as of June 2, 2025 (the "Effective Time"), with the Issuer continuing as the surviving entity and a wholly owned subsidiary of Parent. Read SEC document |
| April 15, 2025 Filed Apr 17, 2025 20:23 UTC | ENSIGN GROUP, INC ENSG · Entity 3521 | GrantCommon Stock | 600 | $0.00 | $0.00 |
DisclosureSEC source: 0001125376-25-000069 · wk-form4_1744921402.xml · nonDerivative · entry 1 Agwunobi John O · CIK 0001627893 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,925.149 F1 · shares: These shares vest in three equal annual installments beginning April 15, 2026. Read SEC document |
| January 15, 2025 Filed Jan 17, 2025 21:54 UTC | ENSIGN GROUP, INC ENSG · Entity 3521 | GrantCommon Stock | 600 | $0.00 | $0.00 |
DisclosureSEC source: 0001125376-25-000009 · wk-form4_1737150837.xml · nonDerivative · entry 1 Agwunobi John O · CIK 0001627893 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,325.149 F1 · shares: These shares vest in three equal annual installments beginning January 15, 2026. Read SEC document |
| November 06, 2024 Filed Nov 8, 2024 21:08 UTC | bluebird bio, Inc. BLUE · Entity 78923 | GrantStock Option (right to buy) · Derivative | 49,850 | $0.00 Strike: $0.44 | $0.00 |
DisclosureSEC source: 0001562180-24-007605 · primarydocument.xml · derivative · entry 2 Agwunobi John O · CIK 0001627893 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 49,850 Underlying: Common Stock · 49,850 shares Expires 2034-11-06 F2 · derivative.exercise_date: This option vests 100% on the earlier of November 6, 2025 or the date of the next annual meeting of stockholders. Read SEC document |
| November 06, 2024 Filed Nov 8, 2024 21:08 UTC | bluebird bio, Inc. BLUE · Entity 78923 | GrantCommon Stock | 24,900 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-24-007605 · primarydocument.xml · nonDerivative · entry 1 Agwunobi John O · CIK 0001627893 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 51,364 F1 · security: These restricted stock units for common stock vest 100% on the earlier of November 6, 2025 or the date of the next annual meeting of stockholders. Read SEC document |
| October 15, 2024 Filed Oct 17, 2024 22:40 UTC | ENSIGN GROUP, INC ENSG · Entity 3521 | GrantCommon Stock | 600 | $0.00 | $0.00 |
DisclosureSEC source: 0001125376-24-000163 · wk-form4_1729204800.xml · nonDerivative · entry 1 Agwunobi John O · CIK 0001627893 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,725.149 F1 · shares: These shares vest in three equal annual installments beginning October 15, 2025. Read SEC document |
| July 15, 2024 Filed Jul 15, 2024 23:36 UTC | ENSIGN GROUP, INC ENSG · Entity 3521 | GrantCommon Stock | 875 | $0.00 | $0.00 |
DisclosureSEC source: 0001125376-24-000127 · wk-form4_1721086597.xml · nonDerivative · entry 1 Agwunobi John O · CIK 0001627893 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,125.149 F1 · shares: These shares vest in three equal annual installments beginning July 15, 2025. Read SEC document |
| April 30, 2024 Filed May 2, 2024 23:08 UTC | ENSIGN GROUP, INC ENSG · Entity 3521 | PurchaseCommon Stock | 0.149 | $117.58 | $17.52 |
DisclosureSEC source: 0001125376-24-000067 · wk-form4_1714691287.xml · nonDerivative · entry 1 Agwunobi John O · CIK 0001627893 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,250.149 F1 · price: Represents shares acquired through an automatic broker-administered dividend reinvestment program, pursuant to a prior election made by the reporting person. Read SEC document |
| April 15, 2024 Filed Apr 17, 2024 22:22 UTC | ENSIGN GROUP, INC ENSG · Entity 3521 | GrantCommon Stock | 875 | $0.00 | $0.00 |
DisclosureSEC source: 0001125376-24-000051 · wk-form4_1713392551.xml · nonDerivative · entry 1 Agwunobi John O · CIK 0001627893 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,250 F1 · shares: These shares vest in three equal annual installments beginning April 15, 2025. Read SEC document |
| January 16, 2024 Filed Jan 18, 2024 22:47 UTC | ENSIGN GROUP, INC ENSG · Entity 3521 | GrantCommon Stock | 875 | $0.00 | $0.00 |
DisclosureSEC source: 0001125376-24-000012 · wk-form4_1705618032.xml · nonDerivative · entry 1 Agwunobi John O · CIK 0001627893 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,375 F1 · shares: These shares vest in three equal annual installments beginning January 16, 2025. Read SEC document |
| October 16, 2023 Filed Oct 18, 2023 21:21 UTC | ENSIGN GROUP, INC ENSG · Entity 3521 | GrantCommon Stock | 875 | $0.00 | $0.00 |
DisclosureSEC source: 0001125376-23-000177 · wk-form4_1697664073.xml · nonDerivative · entry 1 Agwunobi John O · CIK 0001627893 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,500 F1 · shares: These shares vest in three equal annual installments beginning October 16, 2024. Read SEC document |
| July 17, 2023 Filed Jul 19, 2023 21:22 UTC | ENSIGN GROUP, INC ENSG · Entity 3521 | GrantCommon Stock | 875 | $0.00 | $0.00 |
DisclosureSEC source: 0001125376-23-000139 · wk-form4_1689801761.xml · nonDerivative · entry 1 Agwunobi John O · CIK 0001627893 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,625 F1 · shares: These shares vest in three equal annual installments beginning July 17, 2024. Read SEC document |
| June 16, 2023 Filed Jun 20, 2023 20:31 UTC | bluebird bio, Inc. BLUE · Entity 78923 | GrantStock Option (right to buy) · Derivative | 21,600 | $0.00 Strike: $3.81 | $0.00 |
DisclosureSEC source: 0001562180-23-005353 · primarydocument.xml · derivative · entry 2 Agwunobi John O · CIK 0001627893 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,600 Underlying: Common Stock · 21,600 shares Expires 2033-06-16 F2 · derivative.exercise_date: This option vests 100% on the earlier of June 16, 2024 or the date of the next annual meeting of stockholders. Read SEC document |
| June 16, 2023 Filed Jun 20, 2023 20:31 UTC | bluebird bio, Inc. BLUE · Entity 78923 | GrantCommon Stock | 10,790 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-23-005353 · primarydocument.xml · nonDerivative · entry 1 Agwunobi John O · CIK 0001627893 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,464 F1 · security: These restricted stock units for common stock vest 100% on the earlier of June 16, 2024 or the date of the next annual meeting of stockholders. Read SEC document |
| April 17, 2023 Filed Apr 19, 2023 22:38 UTC | ENSIGN GROUP, INC ENSG · Entity 3521 | GrantCommon Stock | 875 | $0.00 | $0.00 |
DisclosureSEC source: 0001125376-23-000077 · wf-form4_168194387119939.xml · nonDerivative · entry 1 Agwunobi John O · CIK 0001627893 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,750 F1 · shares: These shares vest in three equal annual installments beginning April 17, 2024. Read SEC document |
| January 17, 2023 Filed Jan 19, 2023 23:24 UTC | ENSIGN GROUP, INC ENSG · Entity 3521 | GrantCommon Stock | 875 | $0.00 | $0.00 |
DisclosureSEC source: 0001125376-23-000010 · wf-form4_167417066813782.xml · nonDerivative · entry 1 Agwunobi John O · CIK 0001627893 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 875 F1 · shares: These shares vest in three equal annual installments beginning January 17, 2024. Read SEC document |
| June 22, 2022 Filed Jun 23, 2022 22:08 UTC | bluebird bio, Inc. BLUE · Entity 78923 | GrantStock Option (right to buy) · Derivative | 5,000 | $0.00 Strike: $4.46 | $0.00 |
DisclosureSEC source: 0001562180-22-005337 · primarydocument.xml · derivative · entry 2 Agwunobi John O · CIK 0001627893 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 Underlying: Common Stock · 5,000 shares Expires 2032-06-22 F2 · derivative.exercise_date: This option vests 100% on the earlier of June 22, 2023 or the date of the next annual meeting of stockholders. Read SEC document |
| June 22, 2022 Filed Jun 23, 2022 22:08 UTC | bluebird bio, Inc. BLUE · Entity 78923 | GrantCommon Stock | 3,109 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-22-005337 · primarydocument.xml · nonDerivative · entry 1 Agwunobi John O · CIK 0001627893 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,674 F1 · security: These restricted stock units for common stock vest 100% on the earlier of June 22, 2023 or the date of the next annual meeting of stockholders. Read SEC document |
| May 10, 2022 Filed May 11, 2022 23:05 UTC | HERBALIFE LTD. HLF · Entity 4842 | PurchaseCommon Stock | 4,222 | $23.55 | $99,434.01 |
DisclosureSEC source: 0001209191-22-028398 · doc4.xml · nonDerivative · entry 1 Agwunobi John O · CIK 0001627893 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 134,745 F1 · price: This transaction was executed in multiple trades at prices ranging from $23.38 to $23.72. The price reported reflects the weighted average purchase price of $23.5514. The reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected. F2 · balance_after: Balance reflects shares purchased through the Issuer's Herbalife Ltd. Employee Stock Purchase Plan since last reported on Form 4. Read SEC document |
| March 30, 2022 Filed Apr 1, 2022 20:13 UTC | HERBALIFE LTD. HLF · Entity 4842 | Tax withholdingCommon Stock | 1,906 | $30.35 | $57,847.10 |
DisclosureSEC source: 0001209191-22-021974 · doc4.xml · nonDerivative · entry 1 Agwunobi John O · CIK 0001627893 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 129,928 F1 · shares: Units withheld to satisfy the withholding tax obligations due in connection with the vesting of restricted stock units ("RSUs") previously granted to the Reporting Person on March 30, 2020. Read SEC document |
| February 25, 2022 Filed Mar 1, 2022 22:57 UTC | HERBALIFE LTD. HLF · Entity 4842 | GrantCommon Stock | 34,125 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-014239 · doc4.xml · nonDerivative · entry 1 Agwunobi John O · CIK 0001627893 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 131,834 F1 · shares: Consists of restricted stock units ("RSUs") granted under the Herbalife Ltd. 2014 Stock Incentive Plan. The RSUs will vest 20% on February 25, 2023, 20% on February 25, 2024, and 60% on February 25, 2025, subject to continued service through each applicable date. Read SEC document |
| February 21, 2022 Filed Feb 24, 2022 00:15 UTC | HERBALIFE LTD. HLF · Entity 4842 | Tax withholdingCommon Stock | 1,697 | $43.26 | $73,412.22 |
DisclosureSEC source: 0001209191-22-012406 · doc4.xml · nonDerivative · entry 3 Agwunobi John O · CIK 0001627893 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 97,709 F3 · shares: Units withheld to satisfy the withholding tax obligations due in connection with the vesting of RSUs previously granted to the Reporting Person on February 21, 2019. Read SEC document |
| February 20, 2022 Filed Feb 24, 2022 00:15 UTC | HERBALIFE LTD. HLF · Entity 4842 | Tax withholdingCommon Stock | 585 | $43.26 | $25,307.10 |
DisclosureSEC source: 0001209191-22-012406 · doc4.xml · nonDerivative · entry 2 Agwunobi John O · CIK 0001627893 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 99,406 F2 · shares: Units withheld to satisfy the withholding tax obligations due in connection with the vesting of RSUs previously granted to the Reporting Person on February 20, 2020. Read SEC document |
| February 19, 2022 Filed Feb 24, 2022 00:15 UTC | HERBALIFE LTD. HLF · Entity 4842 | Tax withholdingCommon Stock | 1,944 | $43.26 | $84,097.44 |
DisclosureSEC source: 0001209191-22-012406 · doc4.xml · nonDerivative · entry 1 Agwunobi John O · CIK 0001627893 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 99,991 F1 · shares: Units withheld to satisfy the withholding tax obligations due in connection with the vesting of restricted stock units ("RSUs") previously granted to the Reporting Person on February 19, 2021. Read SEC document |
| February 10, 2022 Filed Feb 14, 2022 22:36 UTC | HERBALIFE LTD. HLF · Entity 4842 | Tax withholdingCommon Stock | 6,802 | $41.94 | $285,275.88 |
DisclosureSEC source: 0001209191-22-009425 · doc4.xml · nonDerivative · entry 2 Agwunobi John O · CIK 0001627893 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 101,935 F2 · shares: Units withheld to satisfy tax withholding obligations in connection with the vesting of PSUs. Read SEC document |
| February 10, 2022 Filed Feb 14, 2022 22:36 UTC | HERBALIFE LTD. HLF · Entity 4842 | GrantCommon Stock | 19,565 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-009425 · doc4.xml · nonDerivative · entry 1 Agwunobi John O · CIK 0001627893 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 108,737 F1 · shares: Represents common shares earned by the Reporting Person in connection with the vesting of performance share units ("PSUs") granted under the Herbalife Ltd. 2014 Stock Incentive Plan based on pre-established performance goals for a 2019-2021 performance period. Read SEC document |
| November 11, 2021 Filed Nov 16, 2021 11:24 UTC | bluebird bio, Inc. BLUE · Entity 78923 | OtherStock Option (right to buy) · Derivative | 10,038 | $0.00 Strike: $16.36 | $0.00 |
DisclosureSEC source: 0001628280-21-023459 · wf-form4_163706180346088.xml · derivative · entry 6 Agwunobi John O · CIK 0001627893 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,038 Underlying: Common Stock · 10,038 shares Expires 2031-06-15 F8 · derivative.exercise_price: Represents options to purchase bluebird common stock awarded to the reporting person prior to the Separation. In connection with the Separation, the shares of common stock underlying this award were adjusted pursuant to the EMA to preserve the value associated with the original award (see footnotes 2 and 3). This option was originally granted on June 15, 2021 and shall vest 100% on the earlier of June 15, 2022 or the date of the next annual meeting of the stockholders. The exercise price of the option has been adjusted based on the conversion ratio described in footnotes 2 and 3. F8 · shares: Represents options to purchase bluebird common stock awarded to the reporting person prior to the Separation. In connection with the Separation, the shares of common stock underlying this award were adjusted pursuant to the EMA to preserve the value associated with the original award (see footnotes 2 and 3). This option was originally granted on June 15, 2021 and shall vest 100% on the earlier of June 15, 2022 or the date of the next annual meeting of the stockholders. The exercise price of the option has been adjusted based on the conversion ratio described in footnotes 2 and 3. F8 · derivative.exercise_date: Represents options to purchase bluebird common stock awarded to the reporting person prior to the Separation. In connection with the Separation, the shares of common stock underlying this award were adjusted pursuant to the EMA to preserve the value associated with the original award (see footnotes 2 and 3). This option was originally granted on June 15, 2021 and shall vest 100% on the earlier of June 15, 2022 or the date of the next annual meeting of the stockholders. The exercise price of the option has been adjusted based on the conversion ratio described in footnotes 2 and 3. Read SEC document |
| November 11, 2021 Filed Nov 16, 2021 11:24 UTC | bluebird bio, Inc. BLUE · Entity 78923 | OtherStock Option (right to buy) · Derivative | 3,938 | $0.00 Strike: $31.93 | $0.00 |
DisclosureSEC source: 0001628280-21-023459 · wf-form4_163706180346088.xml · derivative · entry 5 Agwunobi John O · CIK 0001627893 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,938 Underlying: Common Stock · 3,938 shares Expires 2030-06-18 F7 · derivative.exercise_price: Represents options to purchase bluebird common stock awarded to the reporting person prior to the Separation. In connection with the Separation, the shares of common stock underlying this award were adjusted pursuant to the EMA such that the reporting person received options to purchase shares of 2seventy common stock to preserve the value associated with the original award (see footnotes 2 and 3). This option was originally granted on June 18, 2020 and is fully vested as of the date hereof. The exercise price of the option has been adjusted based on the conversion ratio described in footnotes 2 and 3. F7 · shares: Represents options to purchase bluebird common stock awarded to the reporting person prior to the Separation. In connection with the Separation, the shares of common stock underlying this award were adjusted pursuant to the EMA such that the reporting person received options to purchase shares of 2seventy common stock to preserve the value associated with the original award (see footnotes 2 and 3). This option was originally granted on June 18, 2020 and is fully vested as of the date hereof. The exercise price of the option has been adjusted based on the conversion ratio described in footnotes 2 and 3. F7 · derivative.exercise_date: Represents options to purchase bluebird common stock awarded to the reporting person prior to the Separation. In connection with the Separation, the shares of common stock underlying this award were adjusted pursuant to the EMA such that the reporting person received options to purchase shares of 2seventy common stock to preserve the value associated with the original award (see footnotes 2 and 3). This option was originally granted on June 18, 2020 and is fully vested as of the date hereof. The exercise price of the option has been adjusted based on the conversion ratio described in footnotes 2 and 3. Read SEC document |
| November 11, 2021 Filed Nov 16, 2021 11:24 UTC | bluebird bio, Inc. BLUE · Entity 78923 | OtherStock Option (right to buy) · Derivative | 3,938 | $0.00 Strike: $60.78 | $0.00 |
DisclosureSEC source: 0001628280-21-023459 · wf-form4_163706180346088.xml · derivative · entry 4 Agwunobi John O · CIK 0001627893 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,938 Underlying: Common Stock · 3,938 shares Expires 2029-06-06 F6 · derivative.exercise_price: Represents options to purchase bluebird common stock awarded to the reporting person prior to the Separation. In connection with the Separation, the shares of common stock underlying this award were adjusted pursuant to the EMA such that the reporting person received options to purchase shares of 2seventy common stock to preserve the value associated with the original award (see footnotes 2 and 3). This option was originally granted on June 6, 2019 and is fully vested as of the date hereof. The exercise price of the option has been adjusted based on the conversion ratio described in footnotes 2 and 3. F6 · shares: Represents options to purchase bluebird common stock awarded to the reporting person prior to the Separation. In connection with the Separation, the shares of common stock underlying this award were adjusted pursuant to the EMA such that the reporting person received options to purchase shares of 2seventy common stock to preserve the value associated with the original award (see footnotes 2 and 3). This option was originally granted on June 6, 2019 and is fully vested as of the date hereof. The exercise price of the option has been adjusted based on the conversion ratio described in footnotes 2 and 3. F6 · derivative.exercise_date: Represents options to purchase bluebird common stock awarded to the reporting person prior to the Separation. In connection with the Separation, the shares of common stock underlying this award were adjusted pursuant to the EMA such that the reporting person received options to purchase shares of 2seventy common stock to preserve the value associated with the original award (see footnotes 2 and 3). This option was originally granted on June 6, 2019 and is fully vested as of the date hereof. The exercise price of the option has been adjusted based on the conversion ratio described in footnotes 2 and 3. Read SEC document |
| November 11, 2021 Filed Nov 16, 2021 11:24 UTC | bluebird bio, Inc. BLUE · Entity 78923 | OtherStock Option (right to buy) · Derivative | 3,938 | $0.00 Strike: $91.20 | $0.00 |
DisclosureSEC source: 0001628280-21-023459 · wf-form4_163706180346088.xml · derivative · entry 3 Agwunobi John O · CIK 0001627893 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,938 Underlying: Common Stock · 3,938 shares Expires 2028-06-20 F5 · derivative.exercise_price: Represents options to purchase bluebird common stock awarded to the reporting person prior to the Separation. In connection with the Separation, the shares of common stock underlying this award were adjusted pursuant to the EMA such that the reporting person received options to purchase shares of 2seventy common stock to preserve the value associated with the original award (see footnotes 2 and 3). This option was originally granted on June 20, 2018 and is fully vested as of the date hereof. The exercise price of the option has been adjusted based on the conversion ratio described in footnotes 2 and 3. F5 · shares: Represents options to purchase bluebird common stock awarded to the reporting person prior to the Separation. In connection with the Separation, the shares of common stock underlying this award were adjusted pursuant to the EMA such that the reporting person received options to purchase shares of 2seventy common stock to preserve the value associated with the original award (see footnotes 2 and 3). This option was originally granted on June 20, 2018 and is fully vested as of the date hereof. The exercise price of the option has been adjusted based on the conversion ratio described in footnotes 2 and 3. F5 · derivative.exercise_date: Represents options to purchase bluebird common stock awarded to the reporting person prior to the Separation. In connection with the Separation, the shares of common stock underlying this award were adjusted pursuant to the EMA such that the reporting person received options to purchase shares of 2seventy common stock to preserve the value associated with the original award (see footnotes 2 and 3). This option was originally granted on June 20, 2018 and is fully vested as of the date hereof. The exercise price of the option has been adjusted based on the conversion ratio described in footnotes 2 and 3. Read SEC document |
| November 11, 2021 Filed Nov 16, 2021 11:24 UTC | bluebird bio, Inc. BLUE · Entity 78923 | OtherStock Option (right to buy) · Derivative | 10,534 | $0.00 Strike: $55.29 | $0.00 |
DisclosureSEC source: 0001628280-21-023459 · wf-form4_163706180346088.xml · derivative · entry 2 Agwunobi John O · CIK 0001627893 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,534 Underlying: Common Stock · 10,534 shares Expires 2027-06-08 F4 · derivative.exercise_price: Represents options to purchase bluebird common stock awarded to the reporting person prior to the Separation. In connection with the Separation, the shares of common stock underlying this award were adjusted pursuant to the EMA such that the reporting person received options to purchase shares of 2seventy common stock to preserve the value associated with the original award (see footnotes 2 and 3). This option was originally granted on June 8, 2017 and is fully vested as of the date hereof. The exercise price of the option has been adjusted based on the conversion ratio described in footnotes 2 and 3. F4 · shares: Represents options to purchase bluebird common stock awarded to the reporting person prior to the Separation. In connection with the Separation, the shares of common stock underlying this award were adjusted pursuant to the EMA such that the reporting person received options to purchase shares of 2seventy common stock to preserve the value associated with the original award (see footnotes 2 and 3). This option was originally granted on June 8, 2017 and is fully vested as of the date hereof. The exercise price of the option has been adjusted based on the conversion ratio described in footnotes 2 and 3. F4 · derivative.exercise_date: Represents options to purchase bluebird common stock awarded to the reporting person prior to the Separation. In connection with the Separation, the shares of common stock underlying this award were adjusted pursuant to the EMA such that the reporting person received options to purchase shares of 2seventy common stock to preserve the value associated with the original award (see footnotes 2 and 3). This option was originally granted on June 8, 2017 and is fully vested as of the date hereof. The exercise price of the option has been adjusted based on the conversion ratio described in footnotes 2 and 3. Read SEC document |
| November 11, 2021 Filed Nov 16, 2021 11:24 UTC | bluebird bio, Inc. BLUE · Entity 78923 | OtherCommon Stock | 6,241 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-21-023459 · wf-form4_163706180346088.xml · nonDerivative · entry 1 Agwunobi John O · CIK 0001627893 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,565 F1 · security: Represents restricted stock units awarded to the reporting person prior to the separation (the "Separation") of 2seventy bio, Inc. ("2seventy") from bluebird bio, Inc. ("bluebird"). In connection with the Separation, the restricted stock units underlying this award were adjusted pursuant to the Employee Matters Agreement by and between 2seventy and bluebird (the "EMA") such that the reporting person received restricted stock units of 2seventy to preserve the value associated with the original restricted stock unit award (see footnotes 2 and 3). This restricted stock unit award was originally granted on June 15, 2021 and vests 100% on the earlier of June 15, 2022 or the date of the next annual meeting of stockholders. F2 · security: bluebird equity awards granted prior to January 1, 2021 were converted into equity awards of both bluebird and 2seventy. The number of shares underlying the converted bluebird equity awards was determined by multiplying the number of shares underlying the existing bluebird equity award by a fraction, the numerator of which is the volume-weighted average trading price of bluebird common stock (trading "regular way") on the five trading days immediately prior to the distribution date (the "bluebird Pre-Distribution VWAP") and the denominator of which is the sum of (1) the volume-weighted average trading price of 2seventy common stock (trading "regular way") on the five trading days immediately following the distribution date multiplied by the distribution ratio and (2) the volume-weighted average trading price of bluebird bio common stock (trading "regular way") on the five trading days immediately following the distribution date (the "bluebird Post-Distribution VWAP"). F3 · security: bluebird equity awards granted on or after January 1, 2021, such equity awards continued as bluebird equity awards, subject to adjustment. The adjusted number of shares of bluebird common stock underlying such equity awards is equal to the number of shares of bluebird common stock subject to the equity award immediately prior to the distribution multiplied by a fraction, the numerator of which is the bluebird Pre-Distribution VWAP and the denominator of which is the bluebird Post-Distribution VWAP. Read SEC document |
| September 17, 2021 Filed Sep 20, 2021 20:30 UTC | HERBALIFE LTD. HLF · Entity 4842 | PurchaseCommon Stock | 5,000 | $44.90 | $224,516.50 |
DisclosureSEC source: 0001209191-21-056892 · doc4.xml · nonDerivative · entry 1 Agwunobi John O · CIK 0001627893 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 89,172 F1 · price: This transaction was executed in multiple trades at prices ranging from $44.88 to $44.92. The price reported reflects the weighted average purchase price of $44.9033. The reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| August 05, 2021 Filed Aug 9, 2021 20:15 UTC | HERBALIFE LTD. HLF · Entity 4842 | PurchaseCommon Stock | 5,200 | $48.19 | $250,565.12 |
DisclosureSEC source: 0001209191-21-050396 · doc4.xml · nonDerivative · entry 1 Agwunobi John O · CIK 0001627893 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 84,172 F1 · balance_after: Balance reflects shares purchased through the Issuer's Herbalife Ltd. Employee Stock Purchase Plan since last reported on Form 4. Read SEC document |
| June 15, 2021 Filed Jun 17, 2021 20:08 UTC | bluebird bio, Inc. BLUE · Entity 78923 | GrantStock Option (right to buy) · Derivative | 5,000 | $0.00 Strike: $32.83 | $0.00 |
DisclosureSEC source: 0001562180-21-004350 · primarydocument.xml · derivative · entry 2 Agwunobi John O · CIK 0001627893 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 Underlying: Common Stock · 5,000 shares Expires 2031-06-15 F2 · derivative.exercise_date: This option vests 100% on the earlier of June 15, 2022 or the date of the next annual meeting of stockholders. Read SEC document |
| June 15, 2021 Filed Jun 17, 2021 20:08 UTC | bluebird bio, Inc. BLUE · Entity 78923 | GrantCommon Stock | 3,109 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-21-004350 · primarydocument.xml · nonDerivative · entry 1 Agwunobi John O · CIK 0001627893 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,433 F1 · security: These restricted stock units for common stock vest 100% on the earlier of June 15, 2022 or the date of the next annual meeting of stockholders. Read SEC document |
| March 30, 2021 Filed Apr 1, 2021 20:18 UTC | HERBALIFE LTD. HLF · Entity 4842 | Tax withholdingCommon Stock | 1,906 | $45.28 | $86,303.68 |
DisclosureSEC source: 0001209191-21-024099 · doc4.xml · nonDerivative · entry 1 Agwunobi John O · CIK 0001627893 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 78,471 F1 · shares: Units withheld to satisfy tax withholding obligations due in connection with the vesting of restricted stock units previously granted to the Reporting Person on March 30, 2020. Read SEC document |
| February 26, 2021 Filed Mar 3, 2021 01:27 UTC | HERBALIFE LTD. HLF · Entity 4842 | Tax withholdingCommon Stock | 2,206 | $44.98 | $99,225.88 |
DisclosureSEC source: 0001209191-21-016539 · doc4.xml · nonDerivative · entry 1 Agwunobi John O · CIK 0001627893 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,377 F1 · shares: Units withheld to satisfy tax withholding obligations due in connection with the vesting of restricted stock units previously granted to the Reporting Person on February 26, 2018. Read SEC document |
| February 21, 2021 Filed Feb 24, 2021 01:34 UTC | HERBALIFE LTD. HLF · Entity 4842 | Tax withholdingCommon Stock | 566 | $48.33 | $27,354.78 |
DisclosureSEC source: 0001209191-21-013526 · doc4.xml · nonDerivative · entry 3 Agwunobi John O · CIK 0001627893 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 82,583 F3 · shares: Units withheld to satisfy tax withholding obligations due in connection with the vesting of RSUs previously granted to the Reporting Person on February 21, 2019. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.